Do not use in patients w/ type 1 diabetes. Discontinue treatment if ketoacidosis is suspected; consider monitoring & temporary discontinuation in clinical situations predisposing to ketoacidosis (eg, prolonged fasting due to acute illness or surgery); consider monitoring of ketones even if treatment has been interrupted. Increased risk of lactic acidosis. Temporarily discontinue use in case of dehydration. Concomitant use w/ medicinal products that can acutely impair renal function (eg, antihypertensives, diuretics & NSAIDs). Discontinue use prior to or at the time of imaging procedure in patient w/ eGFR >60 mL/min/1.73 m
2 & 48 hr before iodinated contrast media administration in patients w/ moderate renal impairment; do not reinstitute until at least 48 hr afterwards. Discontinue use & institute prompt treatment if necrotizing fasciitis of the perineum (Fournier's gangrene) is suspected. Assess GFR before treatment initiation & regularly thereafter. Temporarily discontinue use in the presence of conditions that alter renal function. Regularly monitor cardiac & renal function in patients w/ stable chronic heart failure. Contraindicated in patients w/ acute & unstable heart failure. Patients for whom empagliflozin-induced BP drop could pose risk (eg, those w/ known CV disease, on antihypertensive therapy w/ history of hypotension or patients ≥75 yr). Carefully monitor vol status (eg, physical exam, BP measurements, lab tests including haematocrit) & electrolytes in case of conditions that may lead to fluid loss (eg, GI illness). Consider temporary treatment interruption until fluid loss is corrected; & in patients w/ complicated UTI. Discontinue treatment at the time of surgery under general, spinal or epidural anaesth; may restart therapy no earlier than 48 hr following surgery or oral nutrition resumption provided that renal function has been re-evaluated & stable. Monitor vit B
12 serum levels in case vit B
12 deficiency (eg, anaemia or neuropathy) is suspected. Minor influence on the ability to drive & use machines; avoid hypoglycaemia particularly in combination w/ sulphonylurea &/or insulin. Hepatic injury. Not recommended during pregnancy. Not to be used during breastfeeding. Not recommended for childn <18 yr. Increased risk of vol depletion in elderly ≥75 yr.